Sugi Predict

Sugi Predict / Compounds / SCHEMBL10149844

SCHEMBL10149844

SCHEMBL10149844

O=c1[nH]nc(-c2ccc(N3CCOCC3)c([N+](=O)[O-])c2)c2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.70
▸ MAPT P10636 7/20 0.70
▸ KMT2A Q03164 4/20 0.70
▸ SMN1; SMN2 Q16637 2/20 0.70
▸ LMNA P02545 4/20 0.62
▸ USP2 O75604 1/20 0.62
▸ HPGD P15428 1/20 0.62
▸ TDP1 Q9NUW8 3/20 0.58
▸ GAA P10253 1/20 0.58
▸ HTT P42858 1/20 0.58
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ CTSB P07858 1/20 0.54
▸ ROCK1 Q13464 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ S1PR1 P21453 1/20 0.48
▸ POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10149846 0.90 ALDH1A1 (0.56) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL10149819 0.89 MAPT (0.56) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL10149834 0.89 ALDH1A1 (0.55) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL3321650 0.89 ALDH1A1 (0.55) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL10149816 0.87 ALDH1A1 (0.53) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL10149821 0.87 ALDH1A1 (0.59) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL10149843 0.85 TP53 (0.56) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL10149852 0.84 ALDH1A1 (0.73) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL10149853 0.84 ALDH1A1 (0.55) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA
SCHEMBL10149827 0.84 ALDH1A1 (0.53) ALDH1A1MAPTKMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171419-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORP (US) 2014-06-19 — — US disclosed
US-20120190668-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLEUCLE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-07-26 — — US disclosed
US-8193177-B2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases ANGION BIOMEDICA CORP. (US) 2012-06-05 — — US disclosed
WO-2011019400-A2 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY ANGION BIOMEDICA CORP. (US) 2011-02-17 — — WO disclosed
US-7879898-B1 treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema ANGION BIOMEDICA CORP. (US) 2011-02-01 — — US disclosed
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. 2010-10-07 — — US disclosed
US-20100137285-A1 SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY ANGION BIOMEDICA CORP. (US) 2010-06-03 — — US disclosed
US-20100137285-A1 SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY ANGION BIOMEDICA CORP. (US) 2010-06-03 — — US disclosed
US-7648978-B2 Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone ANGION BIOMEDICA CORP. (US) 2010-01-19 — — US disclosed
US-7648978-B2 Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone ANGION BIOMEDICA CORP. (US) 2010-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190668-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLEUCLE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY HGF, HDGF, HGFAC ALDH1A1 1510/4885MAPT 4800/4885KMT2A 3997/4885
US-20100137285-A1 SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY HGF, IL2, IL2RA ALDH1A1 978/4885MAPT 3078/4885KMT2A 3896/4885
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES HGF, HDGF, HGFAC ALDH1A1 1992/4885MAPT 4274/4885KMT2A 3623/4885
US-20140171419-A1 ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY HGF, HDGF, MET ALDH1A1 743/4885MAPT 4685/4885KMT2A 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.